Marlyanne M Pol Rodriguez, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Rodriguez’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A96841 · Current
Licensed to practise in California · since 2006 · expires 2028-05-31 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$22,431
Medicare paid this office $22,431 for 158 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 60 | $6,441 | $85 |
| Short return visit (20+ min) | 66 | $4,896 | $56 |
| Destruction of precancer skin growth, 1 growth | 40 | $2,548 | $46 |
| Destruction of skin growth, 1-14 growths | 20 | $1,397 | $70 |
| Biopsy of related skin growth, first growth | 40 | $1,073 | $25 |
See all 7 services
| Return visit (30+ min) | 60 | $6,441 | $85 |
| Short return visit (20+ min) | 66 | $4,896 | $56 |
| Destruction of precancer skin growth, 1 growth | 40 | $2,548 | $46 |
| Destruction of skin growth, 1-14 growths | 20 | $1,397 | $70 |
| Biopsy of related skin growth, first growth | 40 | $1,073 | $25 |
| New patient visit (30+ min) | 14 | $1,040 | $74 |
| Destruction of precancer skin growth, 2-14 growths | 30 | $317 | $2 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 113 | More than 76% of doctors who do this |
| Skin biopsy | 74 | More than 73% of doctors who do this |
Who their Medicare patients are
158 Original Medicare patients in 2024. Average age 74 · Under 65 10% · 85 and older 10% · Women 47% · Also on Medicaid 20% · Health risk score 1.28. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 59% · Coronary heart disease 26% · Diabetes 25% · Cancer 20% · Depression 20% · Chronic kidney disease 18% · Atrial fibrillation 15% · Heart failure 13% · COPD 11% · Stroke 8%.
The office billed $110,182, Medicare allowed $30,566 and paid $22,431; for 570 services of 31 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 158 | 570 | 74 | 1.28 | $110,182 | $22,431 |
| 2023 | 116 | 459 | 74 | 1.11 | $80,130 | $17,290 |
| 2022 | 119 | 502 | 72 | 1.31 | $81,769 | $16,905 |
| 2021 | 107 | 378 | 74 | 1.12 | $74,996 | $14,341 |
| 2020 | 148 | 471 | 73 | 1.13 | $76,673 | $13,380 |
| 2019 | 183 | 803 | 73 | 1.12 | $86,629 | $21,555 |
| 2018 | 156 | 580 | 72 | 1.13 | $47,853 | $15,137 |
| 2017 | 217 | 907 | 72 | 1.37 | $89,696 | $25,165 |
| 2016 | 256 | 1,116 | 73 | 1.15 | $139,951 | $36,143 |
| 2015 | 294 | 1,058 | 73 | 1.19 | $133,506 | $35,315 |
| 2014 | 239 | 994 | 72 | 1.24 | $131,652 | $35,527 |
| 2013 | 139 | 554 | 72 | 1.30 | $70,028 | $17,584 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 49 | $5,962 | $86 |
| Short return visit (20+ min) | 63 | $4,865 | $53 |
| Destruction of precancer skin growth, 1 growth | 42 | $2,842 | $46 |
| Biopsy of related skin growth, first growth | 25 | $714 | $24 |
| Destruction of precancer skin growth, 2-14 growths | 31 | $277 | $2 |
2022: 5 services
| Short return visit (20+ min) | 70 | $5,076 | $55 |
| Return visit (30+ min) | 43 | $4,766 | $81 |
| Destruction of precancer skin growth, 1 growth | 53 | $2,779 | $44 |
| Biopsy of related skin growth, first growth | 29 | $711 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 41 | $301 | $2 |
2021: 6 services
| Short return visit (20+ min) | 72 | $4,613 | $48 |
| Return visit (30+ min) | 28 | $3,849 | $84 |
| Destruction of precancer skin growth, 1 growth | 36 | $1,679 | $39 |
| New patient visit (30+ min) | 12 | $871 | $73 |
| Biopsy of related skin growth, first growth | 21 | $489 | $22 |
| Destruction of precancer skin growth, 2-14 growths | 28 | $169 | $1 |
2020: 7 services
| Short return visit (20+ min) | 79 | $3,699 | $37 |
| Return visit (30+ min) | 48 | $3,662 | $63 |
| Destruction of precancer skin growth, 1 growth | 43 | $1,731 | $38 |
| New patient visit (15+ min) | 23 | $952 | $41 |
| Biopsy of related skin growth, first growth | 30 | $695 | $23 |
| Destruction of skin growth, 1-14 growths | 11 | $665 | $60 |
| Destruction of precancer skin growth, 2-14 growths | 27 | $231 | $1 |
2019: 8 services
| Short return visit (20+ min) | 119 | $6,290 | $39 |
| Return visit (30+ min) | 57 | $4,177 | $62 |
| Destruction of precancer skin growth, 1 growth | 71 | $3,360 | $37 |
| Destruction of skin growth, 1-14 growths | 25 | $1,679 | $58 |
| Biopsy of related skin growth, first growth | 48 | $1,181 | $21 |
| New patient visit (15+ min) | 13 | $593 | $46 |
| Destruction of precancer skin growth, 2-14 growths | 54 | $519 | $2 |
| Short return visit | 15 | $320 | $20 |
2018: 10 services
| Short return visit (20+ min) | 92 | $4,093 | $36 |
| Return visit (30+ min) | 44 | $3,354 | $63 |
| Destruction of precancer skin growth, 1 growth | 54 | $2,496 | $38 |
| Biopsy of single growth of skin and/or tissue | 40 | $1,260 | $28 |
| Destruction of skin growth, 1-14 growths | 15 | $1,001 | $63 |
| New patient visit (30+ min) | 15 | $708 | $47 |
| Biopsy of each additional growth of skin and/or tissue | 15 | $495 | $21 |
| New patient visit (15+ min) | 12 | $494 | $41 |
| Destruction of precancer skin growth, 2-14 growths | 38 | $380 | $2 |
| Short return visit | 12 | $203 | $17 |
2017: 9 services
| Short return visit (20+ min) | 138 | $8,017 | $43 |
| Return visit (30+ min) | 65 | $4,905 | $64 |
| Destruction of precancer skin growth, 1 growth | 80 | $3,667 | $38 |
| Destruction of skin growth, 1-14 growths | 31 | $2,112 | $60 |
| Biopsy of single growth of skin and/or tissue | 54 | $1,687 | $29 |
| New patient visit (30+ min) | 17 | $900 | $53 |
| Biopsy of each additional growth of skin and/or tissue | 19 | $747 | $20 |
| New patient visit (15+ min) | 20 | $733 | $37 |
| Destruction of precancer skin growth, 2-14 growths | 65 | $572 | $2 |
2016: 9 services
| Return visit (30+ min) | 153 | $13,481 | $65 |
| Short return visit (20+ min) | 102 | $5,282 | $41 |
| Destruction of precancer skin growth, 1 growth | 85 | $5,046 | $42 |
| Destruction of skin growth, 1-14 growths | 43 | $3,070 | $63 |
| Biopsy of single growth of skin and/or tissue | 67 | $2,240 | $30 |
| New patient visit (30+ min) | 35 | $2,130 | $61 |
| Destruction of precancer skin growth, 2-14 growths | 70 | $827 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 18 | $637 | $23 |
| New patient visit (15+ min) | 14 | $410 | $29 |
2015: 10 services
| Return visit (30+ min) | 181 | $13,976 | $63 |
| Short return visit (20+ min) | 95 | $4,932 | $42 |
| Destruction of precancer skin growth, 1 growth | 73 | $3,613 | $41 |
| Destruction of skin growth, 1-14 growths | 35 | $2,493 | $61 |
| New patient visit (30+ min) | 36 | $2,261 | $63 |
| Biopsy of single growth of skin and/or tissue | 58 | $2,245 | $35 |
| Destruction of precancer skin growth, 2-14 growths | 61 | $767 | $2 |
| New patient visit (15+ min) | 16 | $627 | $39 |
| Biopsy of each additional growth of skin and/or tissue | 15 | $453 | $23 |
| Short return visit | 11 | $205 | $19 |
2014: 9 services
| Return visit (30+ min) | 185 | $17,608 | $64 |
| Destruction of precancer skin growth, 1 growth | 74 | $3,397 | $39 |
| Destruction of skin growth, 1-14 growths | 41 | $2,832 | $62 |
| Biopsy of single growth of skin and/or tissue | 59 | $2,218 | $32 |
| Short return visit (20+ min) | 42 | $2,132 | $44 |
| New patient visit (30+ min) | 29 | $1,673 | $58 |
| New patient visit (45+ min) | 18 | $1,640 | $91 |
| Destruction of precancer skin growth, 2-14 growths | 58 | $700 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 18 | $488 | $20 |
2013: 8 services
| Return visit (30+ min) | 67 | $5,223 | $62 |
| Short return visit (20+ min) | 52 | $2,373 | $37 |
| Destruction of precancer skin growth, 1 growth | 41 | $1,930 | $39 |
| New patient visit (45+ min) | 15 | $1,691 | $113 |
| New patient visit (30+ min) | 31 | $1,680 | $54 |
| Biopsy of single growth of skin and/or tissue | 26 | $941 | $32 |
| Destruction of skin growth, 1-14 growths | 15 | $819 | $45 |
| Destruction of precancer skin growth, 2-14 growths | 34 | $694 | $3 |
Medicaid work
$1,301 in 2024
Medicaid paid $1,301 for 14 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 14 | $1,301 |
| 2024 | 14 | 1 | 14 | $1,301 |
| 2023 | 12 | 1 | 12 | $538 |
| 2022 | 12 | 1 | 12 | $482 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 12 | $538 |
2022
| Return visit (30+ min) | 12 | $482 |
Drugs they prescribed that Part D paid
$268,814
Pharmacies billed $268,814 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 247) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
195 generic and 52 brand-name prescriptions · $268,814 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira | 13 | $81,576 | $6,275 |
| Dupixent | 16 | $59,605 | $3,725 |
| Clobetasol Propionate | 12 | $598 | $50 |
| Fluocinonide | 12 | $431 | $36 |
| Nystop | 11 | $368 | $33 |
See all 7 drugs
| Humira | 13 | $81,576 | $6,275 |
| Dupixent | 16 | $59,605 | $3,725 |
| Clobetasol Propionate | 12 | $598 | $50 |
| Fluocinonide | 12 | $431 | $36 |
| Nystop | 11 | $368 | $33 |
| Ketoconazole | 22 | $245 | $11 |
| Triamcinolone Acetonide | 22 | $137 | $6 |
Year by year
| 2024 | 247 | 66 | 0% (0) | 21% | $268,814 |
| 2023 | 199 | 53 | 0% (0) | 16% | $183,062 |
| 2022 | 164 | 54 | 0% (0) | 13% | $136,196 |
| 2021 | 194 | 71 | 0% (0) | 10% | $55,786 |
| 2020 | 262 | 70 | 0% (0) | 9% | $32,658 |
| 2019 | 234 | 83 | 0% (0) | 12% | $19,019 |
| 2018 | 339 | 81 | 0% (0) | 22% | $104,021 |
| 2017 | 406 | 109 | 0% (0) | 19% | $138,459 |
| 2016 | 482 | 122 | 0% (0) | 17% | $92,303 |
| 2015 | 550 | 140 | 0% (0) | 23% | $150,304 |
| 2014 | 378 | 109 | None | None | $44,161 |
| 2013 | 237 | 89 | None | None | $26,938 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Humira | 13 | $97,197 | $7,477 |
| Fluocinonide | 17 | $1,269 | $75 |
| Ketoconazole | 25 | $348 | $14 |
| Triamcinolone Acetonide | 19 | $166 | $9 |
| Hydrocortisone | 11 | $145 | $13 |
2022: 3 drugs
| Ciclopirox | 15 | $1,138 | $76 |
| Ketoconazole | 12 | $403 | $34 |
| Triamcinolone Acetonide | 22 | $306 | $14 |
2021: 3 drugs
| Triamcinolone Acetonide | 33 | $303 | $9 |
| Ketoconazole | 17 | $257 | $15 |
| Hydrocortisone | 12 | $58 | $5 |
2020: 5 drugs
| Fluocinonide | 15 | $1,427 | $95 |
| Ketoconazole | 25 | $941 | $38 |
| Nystop | 16 | $797 | $50 |
| Ciclopirox | 16 | $485 | $30 |
| Triamcinolone Acetonide | 34 | $319 | $9 |
2019: 5 drugs
| Tretinoin | 15 | $2,554 | $170 |
| Fluocinonide | 16 | $869 | $54 |
| Clobetasol Propionate | 13 | $775 | $60 |
| Doxepin | 12 | $687 | $57 |
| Triamcinolone Acetonide | 30 | $326 | $11 |
2018: 10 drugs
| Clobetasol Propionate | 18 | $3,721 | $207 |
| Clindamycin-Benzoyl Peroxide | 15 | $3,232 | $215 |
| Tretinoin | 18 | $1,928 | $107 |
| Fluocinonide | 19 | $1,286 | $68 |
| Ketoconazole | 28 | $602 | $22 |
| Triamcinolone Acetonide | 40 | $569 | $14 |
| Methotrexate | 16 | $350 | $22 |
| Gabapentin | 23 | $308 | $13 |
| Acyclovir | 11 | $128 | $12 |
| Hydrocortisone | 12 | $66 | $5 |
2017: 9 drugs
| Clobetasol Propionate | 29 | $4,959 | $171 |
| Fluocinonide | 39 | $3,974 | $102 |
| Tretinoin | 18 | $1,445 | $80 |
| Doxycycline Hyclate | 21 | $1,188 | $57 |
| Clindamycin Phosphate | 15 | $587 | $39 |
| Ketoconazole | 27 | $580 | $21 |
| Triamcinolone Acetonide | 31 | $309 | $10 |
| Hydrocortisone | 19 | $200 | $11 |
| Gabapentin | 12 | $177 | $15 |
2016: 16 drugs
| Acitretin | 13 | $15,611 | $1,201 |
| Tazorac | 12 | $7,933 | $661 |
| Fluocinonide | 28 | $4,627 | $165 |
| Clobetasol Propionate | 19 | $4,398 | $231 |
| Tretinoin | 24 | $3,915 | $163 |
| Fluorouracil | 18 | $2,073 | $115 |
| Doxycycline Hyclate | 22 | $1,984 | $90 |
| Econazole Nitrate | 13 | $1,809 | $139 |
| Triamcinolone Acetonide | 60 | $855 | $14 |
| Ketoconazole | 46 | $854 | $19 |
| Ciclopirox | 15 | $514 | $34 |
| Nystop | 11 | $479 | $44 |
| Prednisone | 13 | $145 | $11 |
| Acyclovir | 12 | $145 | $12 |
| Hydrocortisone | 17 | $135 | $8 |
| Hydroxyzine | 11 | $82 | $7 |
2015: 15 drugs
| Clobetasol Propionate | 34 | $6,671 | $196 |
| Econazole Nitrate | 31 | $6,243 | $201 |
| Fluocinonide | 27 | $3,736 | $138 |
| Desonide | 30 | $3,487 | $116 |
| Fluocinolone Acetonide | 17 | $2,212 | $130 |
| Clindamycin Phosphate | 27 | $1,760 | $65 |
| Tretinoin | 11 | $1,642 | $149 |
| Ciclopirox | 16 | $1,094 | $68 |
| Doxycycline Hyclate | 14 | $1,015 | $72 |
| Triamcinolone Acetonide | 51 | $829 | $16 |
| Ketoconazole | 57 | $810 | $14 |
| Hydroxyzine | 26 | $606 | $23 |
| Pentoxifylline | 13 | $359 | $28 |
| Oxybutynin Chloride | 13 | $176 | $14 |
| Hydrocortisone | 14 | $90 | $6 |
2014: 10 drugs
| Clobetasol Propionate | 36 | $2,721 | $76 |
| Fluocinonide | 26 | $1,956 | $75 |
| Desonide | 19 | $1,613 | $85 |
| Doxycycline Hyclate | 21 | $1,299 | $62 |
| Metronidazole | 11 | $1,282 | $117 |
| Pentoxifylline | 15 | $639 | $43 |
| Triamcinolone Acetonide | 34 | $602 | $18 |
| Hydroxyzine | 19 | $433 | $23 |
| Ketoconazole | 12 | $185 | $15 |
| Prednisone | 16 | $145 | $9 |
2013: 7 drugs
| Cyclosporine Modified | 12 | $2,866 | $239 |
| Clindamycin Phosphate | 11 | $1,714 | $156 |
| Fluocinolone Acetonide | 11 | $1,219 | $111 |
| Clobetasol Propionate | 28 | $773 | $28 |
| Triamcinolone Acetonide | 24 | $572 | $24 |
| Fluocinonide | 11 | $539 | $49 |
| Hydroxyzine | 13 | $156 | $12 |
Money from drug and device companies
$15 in 2023
A payment is not proof that care is biased.
| Pfizer | Cibinqo | $15 | 1 payment
|
See the published payment
| Pfizer | Education · 2023-04-12 | Cibinqo | $15 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1942364377
- Licence
- CA A96841California A96841: Current · expires 2028-05-31
- Trained
- Yale University School of Medicine, 2002
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 450 Broadway St, Pavilion B, 4th Floor M/C 5338, Redwood City, CA, 94063
- NPI first listed
- 2006-12-20
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 450 Broadway St, Redwood City, CA, 94063